Microsoft word - 【英訳】131210_huaren2.doc
Patent and Know-How License Agreement with Huaren Pharmaceutical Co., Ltd.
JMS Co., Ltd. (hereinafter “JMS”) announced that JMS has entered into a Patent and Know-How License
Agreement with Huaren Pharmaceutical Co., Ltd. (hereinafter “Huaren”), Qingdao-based Chinese company,
regarding medical devices and pharmaceutical drugs for Peritoneal Dialysis. 1. Background and Objectives
One of JMS’s major businesses is to develop, manufacture, and sell medical devices and pharmaceutical
drugs for Peritoneal Dialysis treatment (hereinafter “PD System”). Peritoneal Dialysis (“PD”) is a
treatment for patients with chronic renal failure which the patients can undertake daily at their home. PD is
prevalent globally because of less physical strain and constraint in daily life for the patients compared to
Huaren was founded in 1998, and its principally business is to develop, manufacture, and sell injectable
solution, imaging agent, and so on. In 2010, Huaren was listed on Shenzhen Stock Exchange, and started
production and sales of peritoneal dialysate from 2011.
Huaren and JMS will enhance PD business in China by leveraging on JMS’s proprietary know-how in
production and sales of PD system and Huaren’s production capacity and sales channel. 2. Contract briefing
JMS will provide its proprietary technology of PD system to support Huaren’s production and sales.
Huaren will expand its product line using the technology provided by JMS, and pay royalty to JMS
according to its sales of the products.
The PD system which JMS provides its technology is a medical device with simple manual operation for safe
PD, and we hope to support better quality of life for the patients in China with our system. 3. Overview of Huaren
① Company Name Huaren Pharmaceutical Co., Ltd. ② Head Office
No. 187, Zhuzhou Road, Laoshan District, Qingdao, Shandong, China
Production/Sales of large-volume injections including anti-cancer drugs, Production/Export of solution, Development/Production/Sales of new packaging material for pharmaceutical products.
There is no capital, business, and personnel relationship between Huaren and JMS. Huaren is a non-related party for JMS.
【Reference】 - Dialysis market in China - In China, approximately two million people suffer chronic renal failure which requires dialysis treatment such as Hemodialysis or Peritoneal Dialysis, and about 15% of them are undertaking actual treatment. The patients who undertake PD treatment account for 10% of them, approx 30,000 patients. The number of patients with PD treatment is estimated to increase 30 % per year.
Corporate Planning Dept. E-Mail: email@example.com
The forecast in this press release is based on limited information available at the moment of disclosure and contain potential risks and uncertainty such as changes in social conditions. It should be noted that this press release is based on the information available as of disclosure, and may differ in the future.
Gallatin County Unified Health Command Meeting Minutes May 14, 2009 8:00 – 9:00 am Sapphire Room Introductions Mike Layman (Belgrade Urgent Care), Mark Winton, Steph Nelson, Tim Roark, Sid Williamson, Jim Feist, Buck Taylor, Betty Kalakay, Leslie Teachout, Ita Killeen, Pam Shrauger, Patrick Lonergan, Kevin Stickler, Sean Grabbe, Vickie Groeneweg Review prior minutes
VALUTAZIONE DEL PROGRAMMA DI INTERVENTO DI SVILUPPO RELAZIONALE RDI® Di Steven E. Gutstein, The Connections Center, Houston, USA Audrey F. Burgess, The Connections Center, Houston, USA Ken Montfort, The Connections Center, Houston, USA ABSTRACT: Questo studio è il secondo di una serie di studi che valutano l’efficacia dell’Intervento di Sviluppo Relazionale (RDI) per trattare i deficit unici